Secondary human analysis
Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial
Ajla H Kuerec, Weilan Wang, Keona D M Fokke, Lin Yi, Zhigang Lin, Aditi Vaidya, Sohal Pendse, Sornaraja Thasma, Niranjan Andhalkar, Ganesh Avhad, Vidyadhar Kumbhar, Andrea B Maier
GeroScience · 2026 · 48(3):3305–3313
Study at a glance
- Design
- Post-hoc analysis of the randomized double-blind Yi et al. dose-ranging trial
- Population or model
- Healthy middle-aged adults from the parent 80-person trial
- Sample size
- 80 participants
- Intervention
- Parent trial: placebo or NMN 300, 600, or 900 mg/day for 60 days
- Publication type
- Post-hoc clinical-trial analysis
- Evidence class
- human-study
- Research area
- NAD and laboratory associations
- Trial registration
- Parent trial: NCT04823260; CTRI/2021/03/032421
Study endpoints
- Baseline blood NAD associations with hematology, inflammatory, lipid and liver measures
- Associations between NMN-induced NAD change and blood laboratory parameters
Plain-language summary
Key findings
Limitations
Funding and transparency
Funding
The parent clinical trial was fully funded by Aba Chemicals Co. (Shanghai, China) and Abinopharm, Inc. (Connecticut, USA). The post-hoc analysis itself was not funded.
Competing interests
Lin Yi is an employee of Abinopharm, Inc.; R.T. and Zhigang Lin are employees of Aba Chemicals Co. The other authors declare no conflict of interest.
HealthspanX observation
This paper should be linked to, not counted separately from, the Yi parent trial when discussing the number of independent NMN clinical trials.
Interpretive weight
Limited
Post-hoc association analysis from an existing trial; useful for hypothesis generation but cannot establish causality or independent treatment effects.
This record summarizes a publication; it is not medical advice or a claim that a HealthspanX product reproduces the study's results. Report a correction.